The CRB-701 ASCO data call on May 26 is the primary catalyst — watch for response durability and HNSCC subgroup data that could derisk the registrational study. The CBO hire adds M&A and partnership expertise but has no immediate trading implication. Monitor the May 26 webcast for data that could move the stock.
Price Chart
Executive Summary
Corbus Pharmaceuticals appointed Nishant Saxena as its first Chief Business Officer with a two-year employment agreement, granting him 192,300 stock options and 58,300 RSUs as inducement equity. Separately, the company announced a May 26 conference call to discuss updated CRB-701 Phase 1/2 data at ASCO, including response durability and HNSCC subgroup analysis. The filing is routine executive hiring and a scheduled data update — no material financial impact or change in fundamentals.
Key Facts
- Nishant Saxena appointed Chief Business Officer effective May 21, 2026, with a 2-year employment term and $470,000 base salary
- Inducement equity grants: 192,300 stock options (25% cliff at 1 year, then monthly over 36 months) and 58,300 RSUs (25% annual vesting over 4 years)
- Non-compete period of 6 months post-employment; severance of 12 months base salary (3 months if termination before 1-year anniversary) outside Change in Control, 18 months during Change in Control Period
- Brent Pfeiffenberger received initial board equity: 24,700 stock options and 7,500 RSUs, each vesting in 3 equal annual installments
- Conference call scheduled for May 26, 2026 at 8:00 a.m. EDT to discuss updated CRB-701 Phase 1/2 data at ASCO (April 1, 2026 data cut)
- Key pipeline milestones: initiation of registrational study of CRB-701 in second-line HNSCC and completion of CANYON-1 Phase 1b study for CRB-913 (n=240)
Financial Impact
No material financial impact; executive compensation of $470K salary plus equity grants is standard for a C-level hire at a $180M market cap clinical-stage biotech
Risk Factors
- CRB-701 ASCO data may disappoint, particularly if durability or HNSCC subgroup results are weak
- Dilution from 192,300 options and 58,300 RSUs is modest (~0.3% of shares outstanding at $180M market cap) but adds to overhang
- No financial guidance or revenue data in this filing — company remains pre-revenue clinical-stage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-233507 |
| Document: crbp-20260519.htm | 0001193125-26-233507 |
| Document: crbp-ex99_1.htm | 0001193125-26-233507 |
| Document: 0001193125-26-233507-index-headers.html | 0001193125-26-233507 |
| Document: 0001193125-26-233507-index.html | 0001193125-26-233507 |
| Document: 0001193125-26-233507.txt | 0001193125-26-233507 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $4.33 | awaiting T+60 | — | $4.15 (−4.16%) |
Sep 30, 2026 27d ago | SC 13G | $6.34 | awaiting T+60 | — | $4.15 (−34.54%) |
Sep 22, 2026 5w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $4.15 (−47.30%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $4.15 (−48.64%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $4.15 (−48.64%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $4.15 (−58.83%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $4.15 (−56.36%) |
May 26, 2026 22w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $4.15 (−47.53%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $4.15 (−63.94%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $4.15 (−65.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers